Results 41 to 50 of about 463,157 (297)

Myocardial Ischemia and Reperfusion Leads to Transient CD8 Immune Deficiency and Accelerated Immunosenescence in CMV-Seropositive Patients [PDF]

, 2014
Rationale: There is mounting evidence of a higher incidence of coronary heart disease (CHD) in cytomegalovirus (CMV) seropositive individuals. Objective: The aim of this study was to investigate whether acute MI triggers an inflammatory T-cell ...
Bagnall, Alan, Boag, Stephen, Das, Rajiv, Dimmick, Ian, Egred, Mohaned, Fiser, Karel, Hoffmann, Jedrzej, Keavney, Bernard, Martin-Ruiz, Carmen, Murali, Santosh, Pircher, Hanspeter, Shmeleva, Evgeniya, Spyridopoulos, Ioakim, Todryk, Stephen, von Zglinicki, Thomas   +14 more
core   +1 more source

Programmed Cell Death Protein 1/Programmed Cell Death Protein Ligand 1 Immunosuppressants in Advanced Non-Small Cell Lung Cancer Research Progress in Treatment

Frontiers in Pharmacology, 2022
PD-1/PD-L1 play key roles in tumor immune escape and the formation of the tumor microenvironment, and are closely related to the generation and development of tumors.
Feng Li, Feng Li, Binchi Liao, Ting Wang, Tingting Qi, Yixin Wang   +5 more
doaj   +1 more source

PD-1 Inhibitory Receptor Downregulates Asparaginyl Endopeptidase and Maintains Foxp3 Transcription Factor Stability in Induced Regulatory T Cells [PDF]

, 2018
CD4+ T cell differentiation into multiple T helper (Th) cell lineages is critical for optimal adaptive immune responses. This report identifies an intrinsic mechanism by which programmed death-1 receptor (PD-1) signaling imparted regulatory phenotype to ...
Amarnath, Shoba, Berlinguer-Palmini, Rolando, Bogyo, Matthew, Eckhaus, Michael A., Edgington-Mitchell, Laura, Felizardo, Tania C., Flomerfelt, Francis A., Fowler, Daniel H., Gangaplara, Arunakumar, Knight, David, Laurence, Arian, Liniany, Lukasz P., Mallett, Grace, Martinez-Fabregas, Jonathan, Samsel, Leigh A., Shevach, Ethan M., Stathopoulou, Chaido, van Kasteren, Sander I., Watts, Colin, Yim, Joshua J., Zhu, Jinfang   +20 more
core   +2 more sources

Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib

Technology in Cancer Research & Treatment, 2023
Background: Programmed cell death protein-1 inhibitors combined with lenvatinib have become a popular treatment option for patients with unresectable hepatocellular carcinoma.
Jinfeng Wang MM, Man Zhao MM, Guangjie Han MM, Xin Han MM, Jianfei Shi PhD, Lili Mi PhD, Ning Li BM, Xiaolei Yin MM, Xiaoling Duan PhD, Jiaojiao Hou MM, Fei Yin PhD   +10 more
doaj   +1 more source

Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis

Frontiers in Oncology, 2021
BackgroundThe prognostic value of programmed cell death-ligand 1 (PD-L1) in gynecological cancers has been explored previously, but the conclusion remains controversial due to limited evidence.
Chen Zhang, Qing Yang
doaj   +1 more source

PD-L1 Co-Stimulation Contributes to Ligand-Induced T Cell Receptor Down-Modulation on \(CD8^+\) T Cells [PDF]

, 2013
T cell receptor (TCR) down-modulation after antigen presentation is a fundamental process that regulates TCR signal transduction. Current understanding of this process is that intrinsic TCR/CD28 signal transduction leads to TCR down-modulation.
Arce, Frederick, Bennett, Clare L., Bricogne, Christopher, Collins, Mary, Escors, David, Karwacz, Katarzyna, MacDonald, Douglas   +6 more
core   +1 more source

Regulation of the programmed cell death protein 1/programmed cell death ligand 1 axis in relapsing–remitting multiple sclerosis

Brain Communications, 2023
Abstract The programmed cell death protein 1/programmed cell death ligand 1 axis plays an important role in the adaptive immune system and has influence on neoplastic and inflammatory diseases, while its role in multiple sclerosis is unclear.
Thanos Tsaktanis, Mathias Linnerbauer, Lena Lößlein, Daniel Farrenkopf, Oliver Vandrey, Anne Peter, Ana Cirac, Tobias Beyer, Lucy Nirschl, Verena Grummel, Mark Mühlau, Matthias Bussas, Bernhard Hemmer, Francisco J Quintana, Veit Rothhammer   +14 more
openaire   +4 more sources

PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation. [PDF]

, 2016
A new approach to the management of non-small-cell lung cancer (NSCLC) has recently emerged that works by manipulating the immune checkpoint controlled by programmed death receptor 1 (PD-1) and its ligand programmed death ligand 1 (PD-L1).
Booton, R, Cane, P, Cree, IA, Gosney, J, Ibrahim, M, Kerr, K, Lal, R, Lewanski, C, Navani, N, Nicholson, AG, Nicolson, M, Summers, Y   +11 more
core   +2 more sources

Nevi, dysplastic nevi, and melanoma: Molecular and immune mechanisms involving the progression

Tzu Chi Medical Journal, 2022
Melanocytic nevi, dysplastic nevi, and melanoma are all derived from the pigment-producing cells, namely melanocytes. Concerning the clinical spectrum, cutaneous melanoma is the most aggressive skin cancer with a low survival rate, while nevi are the ...
Wei-Wen Sung, Chung-Hsing Chang
doaj   +1 more source

Synthesis and antitumor activity of mechercharmycin A analogues [PDF]

, 2014
Several analogs of the cytotoxic thiopeptide IB-01211 or Mechercharmycin A (1) have been synthetized. The cytotoxicity of 1 and the synthetized analogs was evaluated against a panel of three human tumor cell lines.
Albericio Palomera, Fernando, Aligué i Alemany, Rosa Maria, Altuna, Marta, Cuevas, Carmen, Hernández Romero, Delia, Álvarez Domingo, Mercedes   +5 more
core   +2 more sources